
(AGENPARL) – SILVER SPRING mar 30 maggio 2023 FDA has received adverse event reports after patients used compounded semaglutide.
Fonte/Source: http://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss